Brooks Laboratories Limited (BROOKS) AI Stock Analysis

• Market Cap: ₹4.51B
• Dividend Yield: N/A
• Average Volume (3M): 4.15K
• Price to Earnings (P/E): 391.4
• Beta (1Y): 1.31
• Revenue Growth: 3.86%
• EPS Growth: 50.63%
• Country: IN
• Employees: 293
• Sector: Healthcare
• Sector Strength: 41
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 3.25
• Shares Outstanding: 29,457,249
• 10 Day Avg. Volume: 6,685
• 30 Day Avg. Volume: 4,154
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹159.00
• Price Target Upside: 3.79% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 56 Neutral
• Price Target: ₹159.00 ▲(3.79% Upside)

Brooks Laboratories Limited's stock score is primarily influenced by its technical analysis, suggesting bullish market momentum. However, significant financial challenges and poor valuation metrics offset these positive signals, leading to a moderate overall score.

Brooks Laboratories Limited Business Overview & Revenue Model

Company Description

Brooks Laboratories Limited (BROOKS) is a pharmaceutical company based in India, primarily engaged in the manufacturing and marketing of a broad range of pharmaceutical products. The company specializes in the production of various formulations in the antibiotic, anti-diabetic, cardiovascular, and gastroenterology segments. Brooks Laboratories has established a presence in both domestic and international markets, focusing on delivering quality healthcare solutions.

How the Company Makes Money

Brooks Laboratories Limited generates revenue through the sale of its pharmaceutical products, which include a wide range of formulations across different therapeutic segments. The company's primary revenue streams come from its domestic sales within India and exports to international markets. Brooks Laboratories also engages in contract manufacturing for other pharmaceutical companies, providing additional income. Strategic partnerships and collaborations with other pharmaceutical firms and research institutions further enhance its revenue capabilities by expanding its market reach and product offerings.

Brooks Laboratories Limited Financial Statement Overview

Summary

Despite improved EBIT and EBITDA margins in 2025 and a better debt-to-equity ratio, Brooks Laboratories Limited struggles with negative net income, volatile revenue, and ongoing cash flow issues, indicating financial instability.

Income Statement

Brooks Laboratories Limited has shown inconsistent revenue growth, with a noticeable decline in revenue from 2022 to 2023, followed by a recovery in 2025. Gross profit margins have been volatile, indicating instability in cost management. However, the company has managed to improve its EBIT and EBITDA margins in 2025 compared to previous years, although net profit margins remain negative due to persistent net losses.

Balance Sheet

The company's debt-to-equity ratio has improved as total debt decreased over recent years, suggesting better leverage management. The return on equity remains negative due to ongoing net losses, which is a concern. However, the equity ratio is relatively stable, indicating a strong equity position relative to total assets.

Cash Flow

Cash flow from operations has been negative for several years, but there has been some improvement in 2025. The company has struggled with free cash flow, indicating potential liquidity issues. The operating cash flow to net income ratio remains unfavorable due to sustained losses, although free cash flow has shown slight growth from a very low base.

Breakdown	Mar 2025	Mar 2024	Mar 2022	Mar 2023	Mar 2021
Income Statement
Total Revenue	825.57M	790.12M	900.93M	632.05M	770.68M
Gross Profit	139.22M	60.88M	142.94M	126.02M	218.28M
EBITDA	58.22M	41.73M	-134.50M	-291.68M	12.52M
Net Income	-99.67M	-195.92M	-193.13M	-209.00M	-193.75M
Balance Sheet
Total Assets	1.24B	904.45M	1.96B	1.10B	1.62B
Cash, Cash Equivalents and Short-Term Investments	12.48M	1.25M	23.85M	13.78M	8.84M
Total Debt	75.83M	56.42M	252.59M	65.12M	313.85M
Total Liabilities	255.90M	248.60M	615.91M	356.44M	829.29M
Stockholders Equity	981.04M	655.85M	630.51M	739.53M	791.48M
Cash Flow
Free Cash Flow	-971.00K	-101.20M	-650.53M	-149.58M	-11.55M
Operating Cash Flow	17.62M	-96.81M	-374.41M	-144.91M	44.59M
Investing Cash Flow	-460.41M	1.82M	-249.09M	4.95M	-51.30M
Financing Cash Flow	441.96M	96.01M	640.71M	114.14M	11.59M

Brooks Laboratories Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 153.20
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BROOKS, the sentiment is Positive. The current price of 153.2 is below the 20-day moving average (MA) of 155.50, above the 50-day MA of 145.67, and above the 200-day MA of 142.29, indicating a bullish trend. The MACD of 2.56 indicates Positive momentum. The RSI at 61.45 is Neutral, neither overbought nor oversold. The STOCH value of 55.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:BROOKS.

Brooks Laboratories Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ALBERTDAVD	65 Neutral	₹4.66B	74.06		0.61%	-9.14%	-91.11%
Sector *	65 Neutral	¥341.94B	11.51	-0.17%	2.40%	9.60%	-10.22%
MEDICO	61 Neutral	₹3.41B	33.79		―	4.15%	21.74%
BROOKS	56 Neutral	₹4.51B	391.42		―	3.86%	50.63%
MEDICAMEQ	54 Neutral	₹4.81B	50.94		0.29%	-9.90%	25.41%
ZIMLAB	54 Neutral	₹3.68B	39.17		―	-3.36%	-47.58%
NECLIFE	43 Neutral	₹3.27B	30.02		―	-0.74%	-2375.84%